


CRYO-CELL KEY PERFORMANCE HIGHLIGHTS Fiscal Years 2003 - 2011



- FY 2003
 - \$7.5M Net Losses on \$7.5M Revenue
- FY 2003 – FY 2010
 - 117% Revenue growth
- FY 2004 – Q211
 - 20 out of 30 Quarters of operating profitability
 - CCEL expands global affiliate network to 22
- FY 2007- Q211
 - CCEL commercializes discovery of Cella world's first and only menstrual stem cell service
 - Builds expansive intellectual property portfolio
 - Establishes self-funded R&D business model
 - Formalizes 11 Cella R&D partnerships
 - Expands product line to 6
- Q211 Earnings Release
 - 10 consecutive quarters of profitability
 - 2 quarters of double-digit unit growth
 - 2 quarters of revenue growth
 - Approximately \$3.3 million in cash
 - No long-term debt
 - CCEL share price closes May 31, 2011 at \$3.67
 - year-over-year increase of 194%
 - Over 240,000 clients worldwide

